Your browser doesn't support javascript.
Messenger RNA Nanovaccine in Cancer Immunotherapy
Cancer Nanotechnology ; : 253-269, 2022.
Article in English | Scopus | ID: covidwho-20238639
ABSTRACT
During the past 2 years, messenger RNA (mRNA) nanovaccine has shown its remarkable antiviral efficacy, rapid manufacture, and good safety profile for preventing coronavirus infection. Meanwhile, intracellular delivery of mRNA-based cancer vaccine starts to show great potential to elicit antitumor immunity. mRNA encoding tumor antigens, delivery vehicles, and immune adjuvants are the key components of mRNA cancer vaccine. To achieve robust antitumor efficacy, mRNA encoding tumor antigens need to be efficiently delivered and translated in dendritic cells with concurrent innate immune stimulation to promote antigen presentation. Compared with other types of tumor vaccines, mRNA nanovaccine is featured by efficient antigen expression, high potential for rapid development, low-cost manufacture, and safe administration. In this chapter, we mainly focus on the mRNA synthesis, mRNA modification, delivery vectors with immune-stimulating features, and tumor antigen selection and discuss the future direction of mRNA nanovaccine in cancer immunotherapy. © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2023.
Keywords

Full text: Available Collection: Databases of international organizations Database: Scopus Topics: Vaccines Language: English Journal: Cancer Nanotechnology Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: Scopus Topics: Vaccines Language: English Journal: Cancer Nanotechnology Year: 2022 Document Type: Article